Participation in clinical trials and research is the only way we can hope to find cures for diseases such as Alzheimer's disease, and promote normal healthy brain and body aging for all!
Alzheimer's Disease Clinical Trials
For more information about participating in a clinical trial, please contact Shani Bardach, Clinical Trials and Outreach Coordinator, at email@example.com or (859) 323-1331.
A4: Anti-Amyloid for Asymptomatic Alzheimer’s
The purpose of the A4 study is to evaluate the study treatment (solanezumab) for people with normal cognition who are at risk for developing Alzheimer’s disease on the basis of having biomarker evidence of amyloid. This study will test the hypothesis that decreasing amyloid burden during the preclinical stages of Alzheimer’s disease will delay future cognitive decline. Participants will receive treatment for 3 years with either the anti-amyloid infusion drug or the placebo. (http://www.a4study.org/).
- You may be eligible to participate if: You are 65-85 years old, have normal cognition, and are able to have an MRI scan.
The purpose of the Gemfibrozil study is to evaluate whether the use of gemfibrozil, a commonly used FDA-approved cholesterol lowering medication, can alter microRNA levels that may play a role in the development of Alzheimer’s disease. Participation in this research study involves nine visits to the clinic over approximately one year.
- You may be eligible to participate if: you are between 65 and 90 years of age, have either a diagnosis of mild cognitive impairment or have normal memory and thinking, are in good general health, and are not currently taking a cholesterol lowering mediation.
The purpose of the FYN/Connect study is to test whether an oral, experimental drug, AZD0530 (saracatinib), will slow progression in mild-stage Alzheimer’s disease. Participation in this research study involves a six week screening period followed by a year of treatment. (http://www.adcs.org/studies/Connect.aspx)
- You may be eligible to participate if: You are 55-85 years of age and have a diagnosis of mild Alzheimer’s disease.
The purpose of NOBLE is to evaluate an investigational drug for patients with mild to moderate Alzheimer’s disease. Participants will receive the study drug or placebo. The study drug may work by protecting brain cells which would result in improved memory, but this has not been proven yet. This study is to find out if the medication is both safe and effective for the target population. Participation in this research study involves 14 visits over 62 weeks. (http://www.adcs.org/studies/Noble.aspx).
- You may be eligible to participate if: You are 55-85 years of age, have a current diagnosis of Alzheimer’s disease, and are currently taking Aricept (donepezil) or Exelon (rivastigmine).